A Phase 1b Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Latest Information Update: 07 Dec 2021
At a glance
- Drugs AC 0058 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors ACEA Biosciences
Most Recent Events
- 25 Mar 2019 New trial record